Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date.

26 Similarly, in KEYNOTE-966, those with PD-L1 combined positive score ≥1 who received pembrolizumab trended towards longer overall survival compared to those who received placebo but, again, did not reach statistical significance (HR = 0.85, 95% CI = 0.72–1.00). 34 At this point, more information is needed to determine which patients most benefit from the addition of immunotherapy to treatment.

also in 111,027 other papers